Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:15 PM
Ignite Modification Date:
2025-12-24 @ 12:15 PM
NCT ID:
NCT01457261
Eligibility Criteria:
Inclusion Criteria:
* diagnosis of definite or probable idiopathic pulmonary fibrosis as defined by the ATS/ERS consensus criteria
Exclusion Criteria:
* co-existent respiratory disease
* use of B2 agonists in preceding two weeks
* DLco and/or FVC falling outside the criteria for either mild or severe IPF.
* Ongoing involvement in clinical trials assessing novel IPF therapies.
* Previous adverse reaction to short or long acting β2 agonist.
* Pregnancy or active breast feeding
* Any contraindication to taking inhaled beta-2 adrenoceptor agonists (especially salbutamol) as listed in the British National Formulary will not be entered into this study.
* an acute respiratory exacerbation requiring emergency room treatment and/ or hospitalisation within four weeks of visit 1 (screening visit)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT01457261
Study Brief:
Protocol Section:
NCT01457261